Overcoming acquired drug resistance in colorectal cancer cells by targeted delivery of 5-FU with EGF grafted hollow mesoporous silica nanoparticles
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Acquired drug resistance (ADR) can be developed in colorectal cancer cells after 5-fluorouracil (5-FU) treatment and diminish the effectiveness of chemotherapy. In this work, acquired 5-FU resistance in the colorectal cancer cell line SW480 was obtained with the up-regulation of dihydropyrimidine dehydrogenase (DPYD) gene expression which can convert 5-FU to its inactive metabolite. To overcome ADR in colorectal cancer, hollow mesoporous silica nanoparticles (HMSNs) grafted with epidermal growth factor (EGF) were used as nanocarriers to deliver 5-FU to colorectal cancer cells with acquired drug resistance. The effect and mechanism of 5-FU loaded EGF grafted HMSNs (EGF-HMSNs-5-FU) in overcoming acquired drug resistance in SW480/ADR cells were studied. The EGF-HMSNs were demonstrated to be specifically internalized in EGFR overexpressed SW480/ADR cells via a receptor-mediated endocytosis and can escape from endo-lysosomes. The EGF-HMSNs-5-FU exhibited much higher cytotoxicity on SW480/ADR cells than HMSNs-5-FU and free 5-FU while the plain HMSNs did not show significant cytotoxicity. The mechanism of EGF-HMSNs-5-FU in overcoming drug resistance in SW480/ADR cells could be attributed to the specific internalization of EGF-HMSNs-5-FU in EGFR overexpressed cells which can lead to high intracellular drug accumulation and cause cell death through S phase arrest.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Fluorinated pyrimidines, a new class of tumour-inhibitory compounds
HEIDELBERGER, C., CHAUDHURI, N. K., DANNEBERG, P., MOOREN, D., GRIESBACH, L., DUSCHINSKY, R., SCHNITZER, R. J., PLEVEN, E., & SCHEINER, J. (1957) · Nature · doi:10.1038/179663a0 · Cited by 1,603
Cited by
Mesoporous Silica Nanoparticles: A Comprehensive Review on Synthesis and Recent Advances
Narayan, R., Nayak, U. Y., Raichur, A. M., & Garg, S. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030118 · Cited by 942
Novel strategies to reverse chemoresistance in colorectal cancer
Ma, S., Zhang, J., Yan, T., Miao, M., Cao, Y., Cao, Y., Zhang, L., & Li, L. (2023) · Cancer Medicine · doi:10.1002/cam4.5594 · Cited by 108
Engineered nanoparticles for imaging and drug delivery in colorectal cancer
Pavitra, E., Dariya, B., Srivani, G., Kang, S.-M., Alam, A., Sudhir, P.-R., Kamal, M. A., Raju, G. S. R., Han, Y.-K., Lakkakula, B. V. K. S., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.017 · Cited by 102
Nano drug delivery strategy of 5-fluorouracil for the treatment of colorectal cancer
Chandran, S. P., Natarajan, S. B., Chandraseharan, S., & Mohd Shahimi, M. S. B. (2017) · Journal of Cancer Research and Practice · doi:10.1016/j.jcrpr.2017.02.002 · Cited by 97
Liu, W., Zhu, Y., Wang, F., Li, X., Liu, X., Pang, J., & Pan, W. (2018) · Royal Society Open Science · doi:10.1098/rsos.181027 · Cited by 59
Metadata
- Authors
- Chen, L., She, X., Wang, T., He, L., Shigdar, S., Duan, W., & Kong, L.
- Venue
- Nanoscale
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2015
- Volume
- 7
- Issue
- 33
- Pages
- 14080-14092
- ISSN
- 2040-3364 (ISSN-L)
- 2040-3372
- OpenAlex
- W1914272705
- Cited by
- 82
- References
- 2
- FWCI
- 2.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overcoming acquired drug resistance in colorectal cancer cells by targeted delivery of 5-FU with EGF grafted hollow mesoporous silica nanoparticles. https://app.cochat.ai/papers/10.1039/c5nr03527a
- The paper
- Chen, L., She, X., Wang, T., He, L., Shigdar, S., Duan, W., & Kong, L. (2015). Overcoming acquired drug resistance in colorectal cancer cells by targeted delivery of 5-FU with EGF grafted hollow mesoporous silica nanoparticles. Nanoscale. https://doi.org/10.1039/c5nr03527a
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.